Shafaat A. Rabbani, MD

Primary Axis: 
Musculoskeletal Disorders
Email: 
Email contact form
Research Focus: 

The focus of research in Dr. Rabbani's laboratory is to investigate the progression of hormone dependent malignancies (breast and prostate cancer). Toward these objectives, the role of urokinase (uPA) and parathyroid hormone related peptide (PTHrP) in the process of tumor invasion, growth and metastasis are being examined. Using our well established models of breast and prostate cancer which closely mimics the behavior of these cancers including their propensity to develop skeletal metastasis, we are examining the efficacy of small molecules, peptides, monoclonal antibodies, oligonucleotides, and gene therapy for further evaluation in patients with these common cancers.Urokinase, parathyroid hormone, breast and prostate Cancers, skeletal metastases, translational research

Keywords: 
Urokinase, parathyroid hormone, breast and prostate Cancers, skeletal metastases, translational research
Location: 
Royal Victoria Hospital
Publications:
Ateeq B, Unterberger A, Szyf M, Rabbani SA. Pharmacological inhibition of DNA methylation induces pro-invasive and pro-metastatic genes in vitro and in vivo. Neoplasia 10(3): 266-278; 2008.
Shukeir N, Pakneshan P, Chen G, Szyf M, Rabbani SA. Alteration of the methylation status of tumor promoting gene decreases prostate cancer cell invasiveness and tumorigenesis in vitro and in vivo. Cancer Research 66(18): 9202-9210; 2006.
Guo YJ, Higazi AAR, Arakelian A, Sachais BS, Cines D, Goldfarb RH, Jones TR, Kawan H, Mazar AP, Rabbani SA. A peptide derived from the non-receptor binding region of urokinase plasminogen activator (uPA) inhibits tumor progression and angiogenesis and induces tumor cell death in vivo. FASEB J 14: 1400-1410; 2000.